Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after ...

Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate.. Atara ...

Atara Biotherapeutics Announces Pricing of $16 Million Offering. THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its ...

THOUSAND OAKS, Calif., May 05, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Workforce reductions are an almost annual occurrence at Atara. The biopharma waved goodbye to 20% of its staff in 2022 and then shrunk its head count by a further 25% last year as it moved its ...

THOUSAND OAKS, Calif., January 21, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Atara's CEO, Cokey Nguyen, Ph.D., expressed confidence in eventually obtaining marketing approval for EBVALLO and filing for ...

Atara Biotherapeutics (ATRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 1, 2024 ...

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to approve its immunotherapy Ebvallo. Read more here.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform ...